Enhancement of CD117-Targeted Bispecific T-cell Engagement by CD33-Targeted Bispecific T-cell Costimulation in Acute Myeloid Leukemia
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Acute myeloid leukemia (AML) originates from the hematopoietic stem and progenitor cell compartment and is associated with an overall poor clinical outcome. T cell-engaging bispecific antibodies (TCE), binding to a tumor-associated antigen and to CD3, redirect T cells to target antigen-expressing cells in an MHC/TCR-independent fashion. The development of TCEs for clinical application is facing several challenges. First, it is difficult to identify a tumor-selective, non-MHC-presented tumor target, not expressed on the tissue of tumor origin, thus limiting specificity. Second, CD3-directed TCEs do not provide a second, T cell-activating signal, such as the stimulation of CD28 or 41BB, thus possibly limiting T-cell efficacy. To address both aspects, we generated a CD33xCD28 IgG4-scFv2 with CD28 agonistic activity and tested it in combination with a previously by us reported CD117xCD3 TCE in AML. Combining these two bispecific antibodies significantly improved T cell-mediated lysis of AML cell lines and primary AML samples by enhancing T-cell activation, proliferation, and cytokine release in vitro. Furthermore, the addition of CD33xCD28 IgG4-scFv2 showed faster time to cell attachment, increased lytic events, and improved specificity toward double-target-expressing cells. In summary, the data indicate that combining costimulation via a second tumor-associated antigen to CD3-TCEs enhances T-cell lytic activity and simultaneously increases specificity against double-target-expressing AML cells. SIGNIFICANCE: Current TCEs lack costimulatory signaling. The here-described CD33xCD28 IgG4-scFv2 delivers target-selective costimulation and enhances activation, proliferation, cytokine release, and cytotoxicity when used in combination with CD117xCD3 TCE in AML in vitro. Furthermore, the dual tumor-associated antigen targeting improves therapeutic specificity by preferentially eliminating CD117+CD33+ cells, possibly allowing improved bispecific antibody-mediated AML therapy.
Fields of Study & Subjects
Monoclonal and Polyclonal Antibodies Research
Acute Myeloid Leukemia Research
Protein Degradation and Inhibitors
Publication details
- Journal / source
- Cancer Research Communications
- Volume
- 6
- Issue
- 4
- Pages
- 946–960
- Publication date
- 30 March 2026
- Language
- EN